EFFICACY	SAFETY	ZUMA-2	OTHER	STUDY DESIGN
30 ORR & CR Rate demonstrated in ZUMA-2 93% & 67%	20 Grade ≥3 CRS 13%	10 What bridging therapy allowed in ZUMA-2 BTK (ibrutinib or acalabrutinib and steroids)	20 Number of Days for Peak Level of Anti-CD19 CAR- T cells 7-14 days	10 Primary Endpoints Objective Response Rate (ORR)
20 Median PFS 25.8 months	30 Grade ≥3 ICANS 33%	30 Exclusion Criteria Active or Serious infection, Prior Allogeneic stem cell transplant, Detectable cerebrospinal fluid malignant cells or brain mets, History of CNS lymphoma or CNS disorders	10 Patients in the primary analysis and total treated in the study 60 & 68 patients	20 Secondary Endpoints Duration of Response (DOR), Overall Survival (OS), Progression Free Survival (PFS) and severity of AEs
10 Median OS 46.6 months	10 Recommendations for Severe CRS and Severe Neurotoxicity Echocardiogram to assess cardiac function, consider intensive care support	20 Median number of prior lines of therapy 3 lines of therapy	30 What is the dosage of Tecartus for MCL 2 x 10⁶ Anti-CD19 CAR T cells/kg of bodyweight with a max of 2 x 10⁸ Anti-CD19 CAR T cells /kg of bodyweight	30 Inclusion criteria MCL, ≥18 years, Disease progression after last regimen or refractory disease to most recent therapy, Prior anthracycline or bendamustine-containing chemotherapy, anti-cd20 monoclonal antibody therapy and a BTKi (ibrutnib or acalabrutinib)

Jeopardy - Tecartus

How many teams are playing ?
Time given to answer each question ?